医学
认知
多发性硬化
间充质干细胞
临床试验
细胞疗法
肿瘤科
物理医学与康复
生物信息学
内科学
干细胞
病理
免疫学
精神科
生物
遗传学
作者
Jason A. Berard,Mark S. Freedman,Ruth Ann Marrie,James Marriott,Harold L. Atkins,David Szwajcer,David W. Courtman,Simon Thebault,Lisa A.S. Walker
标识
DOI:10.1016/j.msard.2022.103779
摘要
Mesenchymal stem cell (MSC) therapies are being evaluated in multiple sclerosis (MS) for possible neural repair. To date, the potential benefits on cognition have received little attention. The objective of the current study was to comprehensively evaluate cognition before and after MSC therapy in those with MS as part of a double-blind, phase II clinical trial.Twenty-eight individuals with a confirmed diagnosis of MS were randomly assigned into two study arms. Cognition was evaluated using an expanded Minimal Assessment of Cognitive Function in Multiple Sclerosis (MACFIMS) battery. The battery was administered at Week 0, Week 24, and Week 48 and results were analysed at the group and individual level.No detectable effect of MSC-mediated neural repair was noted in the short-term with respect to cognition, although some cognitive stability or improvement was observed. Decline was noted in some cognitive areas immediately following the procedure at Week 24; though these were temporary with performance returning to baseline levels at Week 48.While MSC therapy does not lead to improvement in cognition, at least in the short-term, neither does the procedure have lasting deleterious effects. The current findings lend support to the safety and feasibility of MSC therapy as a potentially viable treatment option for individuals with MS.
科研通智能强力驱动
Strongly Powered by AbleSci AI